Oct 10, 2023
- Pharmaceuticals
- R&D
Roche Announces Updates on Retinal Vein Occlusion (RVO) for Vabysmo
TOKYO, October 10, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche issued a press release regarding long-term results of its two phase III clinical trials (BALATON study and COMINO study) for Vabysmo® (faricimab) for retinal vein occlusion (RVO).
Please refer to the link below for details of the press release:
Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
https://www.roche.com/media/releases/med-cor-2023-10-10
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp